The Pazdurs in their garden in Bethesda, with their dog, Cleo.The dog's full name is Cleopatra, Queen of Denial.The job interview wouldn't last more than 15 minutes, Richard Pazdur believed.
Roche and Upsher-Smith Laboratories Inc., through its wholly-owned U.K. subsidiary Proximagen Ltd., announced a worldwide agreement for the further development of a novel, oral small molecule inhibitor of Vascular Adhesion Protein 1, a cell-adhesion molecule that may be effective in the treatment of inflammatory disease. The VAP-1 inhibitor is currently in phase II clinical development.
The European Medicines Agency accepted a marketing authorization application for review of anamorelin HCI, a novel, orally active selective ghrelin receptor agonist under development for the treatment of anorexia, cachexia, or unintended weight loss in non-small cell lung cancer patients. Anamorelin is being developed by Helsinn.
Morphotek Inc., a subsidiary of Eisai Inc., entered into an agreement with the Targeted Alpha Therapy Group at the University of Gothenburg in Sweden to collaborate on the research and development of farletuzumab as an alpha therapy vector being studied for radioimmunotherapy in ovarian cancer.
THE NATIONAL HEALTH CARE ANTI-FRAUD ASSOCIATION today presented its Investigation of the Year Award to a team of federal agencies together with a private health insurer for their collaborative work on the case of United States of America v. Farid Fata, MD.
The European Commission granted marketing authorization for Kyprolis (carfilzomib) in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy.
THE AMERICAN SOCIETY FOR RADIATION ONCOLOGY published a new template that standardizes and streamlines the creation of patient-focused plans for long-term cancer survivor care following radiation therapy.
WEST CANCER CENTER celebrated the grand opening of its East Campus location with a ribbon-cutting ceremony Nov. 17.
MANIPAL HOSPITALS' corporate and teaching facilities in India will adopt IBM's Watson for Oncology, a cognitive computing platform that analyzes data to identify evidence-based treatment options.
FOX CHASE CANCER CENTER - Temple Health formed a partnership with Accutest Research Laboratories for joint work on clinical trials.